Enrollment has been completed for a Phase 2b trial that’s testing LYT-100 (deupirfenidone), PureTech Health’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The trial, called ELEVATE IPF (NCT05321420), is assessing the safety, efficacy, and dosing regimen of LYT-100 in 240 adults with IPF, compared with a placebo.
Low doses of controlled-release morphine, a natural opioid derived from the opium poppy, may reduce the frequency of daytime cough in people with idiopathic pulmonary fibrosis (IPF), according to data from a Phase 2 clinical trial. In the trial, called PACIFY COUGH (NCT04429516), patients who were experiencing persistent…
Pliant Therapeutics’ Phase 2b BEACON-IPF trial testing bexotegrast, an investigational oral treatment, in people with idiopathic pulmonary fibrosis (IPF) is now a pivotal, adaptive Phase 2b/3 trial. Accepted by European Union and global health authorities, the implementation of the adaptive design is expected to markedly shorten the therapy’s…
Almee, a behavioral therapy app designed to help ease anxiety in people with pulmonary fibrosis (PF), has been granted breakthrough device designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to medical devices that have the potential to provide a more effective treatment or…
GRI Bio has been given the green light to begin a Phase 2a clinical trial testing its lead program candidate GRI-0621, a natural killer T-cell (NKT)-targeted therapy, in people with idiopathic pulmonary fibrosis (IPF) in the U.K. The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) cleared the…
Adults with idiopathic pulmonary fibrosis (IPF) who had greater diversity of mouth bacteria tended to have worse lung function and a higher risk of death than did those with a less diverse bacteria population in their mouths, a new large-scale study shows. Interestingly, however, those with a higher proportion…
Acute exacerbations, or sudden bouts of symptom worsening, increase the mortality risk after lung transplantation in people with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), a study reports. While a lung transplant is considered an effective treatment for ILDs, these findings “suggest that caution is required during decision-making,…
Sweden-based Vicore Pharma has granted exclusive rights to pharmaceutical company Nippon Shinyaku to develop and commercialize its treatment candidate C21 (VP01) in Japan, with an initial focus on idiopathic pulmonary fibrosis (IPF). Nippon will be operationally and financially responsible for the development of C21 in Japan, where…
Five new Pulmonary Fibrosis Foundation (PFF) scholars will each use $100,000, granted over the course of two years, to research new ways to diagnose, treat, or manage pulmonary fibrosis (PF). The six-year-old program awards grants each year to help scientists improve their understanding of PF, a chronic…
A Phase 2a clinical trial has finished testing the experimental therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF), according to its developer, Endeavor BioMedicines. Endeavor did not include in its announcement any specific data from the trial, but John Hood, PhD, the company’s co-founder, CEO, and…
Get regular updates to your inbox.
